Onconetix Insider Filing: Vesting Change and 618 Restricted Shares Granted
Rhea-AI Filing Summary
Onconetix, Inc. (ONCO) Form 4 filing reports changes to director Timothy Ramdeen's restricted stock awards. The filing shows the Original Award granted 9/26/2024 had its vesting date changed on 08/15/2025 from vesting in full on 08/31/2025 to vesting in full on 08/31/2026, contingent on continued service as a non-employee director. The issuer effected a 1-for-85 reverse stock split on 06/13/2025 and all amounts are shown post-split. The filing also reports a separate restricted stock award of 618 shares that will vest in full on 08/31/2026, subject to continued service. Reported transactions on 08/15/2025 include acquisitions and a disposition, with 658 shares shown as beneficially owned following the transactions.
Positive
- New restricted stock award of 618 shares granted with vesting on 08/31/2026
- All amounts presented post 1-for-85 reverse split (reverse split occurred 06/13/2025)
- Clear disclosure of vesting conditions tying awards to continued service as a non-employee director
Negative
- Original restricted award vesting date was delayed from 08/31/2025 to 08/31/2026
- Disposition of 40 shares is reported on 08/15/2025
Insights
TL;DR: Director's equity award vesting was extended and a new restricted award was granted; post-split share counts updated.
The filing documents a modification to an existing restricted stock award and a new restricted stock grant for a non-employee director. The key numeric disclosures: amounts are presented on a post 1-for-85 reverse split basis and the director holds 658 shares beneficially after the reported activity. The modified Original Award now vests 08/31/2026 rather than 08/31/2025, and a new 618-share award vests 08/31/2026, both conditioned on continued board service. These changes affect outstanding insider-held equity timing but do not disclose cash consideration or acceleration triggers.
TL;DR: Governance action: vesting schedule extended and new grant tied to board service; disclosure is routine for director compensation.
The filing is a standard Section 16 disclosure showing a director-level equity compensation adjustment and an additional grant. The modification ties vesting to continued non-employee director service through 08/31/2026. The report clearly notes the 1-for-85 reverse split on 06/13/2025 and that figures are post-split. No amendments to other award terms are referenced beyond the vesting date change.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock | 39 | $0.00 | -- |
| Grant/Award | Common Stock | 618 | $0.00 | -- |
Footnotes (1)
- Represents a restricted stock award originally granted to the Reporting Person on September 26, 2024 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date.
